Suggested remit: To appraise the clinical and cost effectiveness of vadadustat within its marketing authorisation for treating anaemia in adults with chronic kidney disease.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
| Process |
STA Standard
|
| ID number |
3821
|
Provisional Schedule
| Committee meeting: 1 |
11 September 2024 |
| Expected publication |
20 November 2024 |
Project Team
| Project lead |
Vonda Murray |
Email enquiries
| External Assessment Group |
Peninsula Technology Assessment Group (PenTAG), University of Exeter |
Stakeholders
| Companies sponsors |
MEDICE Arzneimittel Pütter GmbH & Co |
| |
Akebia Therapeutics Inc |
| Others |
Department of Health and Social Care |
| |
Health Technology Wales (HTW) |
| |
NHS England |
| Patient carer groups |
Kidney Care UK |
| |
Kidney Research UK |
| Professional groups |
Royal College of Radiologists |
| |
Royal College of Physicians |
| Associated guideline groups |
None |
| Associated public health groups |
None |
| Comparator companies |
Amgen UK (darbepoetin alfa) confidentiality agreement not signed, not participating |
| |
Janssen-Cilag (epoetin alfa) confidentiality agreement not signed, not participating |
| |
Pfizer (epoetin zeta) confidentiality agreement not signed, not participating |
| |
Roche Products UK (epoetin beta, methoxy polyethylene glycol-epoetin beta) confidentiality agreement not signed, not participating |
| Evidence review group |
Peninsula Technology Assessment Group (PenTAG) |
| General commentators |
All Wales Therapeutic and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health - Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
None |
|
Date
|
Update
|
|
22 April 2024
|
Evidence submission received |
|
12 February 2024
|
Invitation to participate |
|
15 December 2023 - 12 January 2024
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 2 |
|
11 December 2023
|
Draft scope documents |
|
13 September 2023
|
Please note that following on from information received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during mid-March 2024 when we will write to you about how you can get involved. |
|
25 July 2023
|
Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course.
In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes. |
|
16 May 2023
|
Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Vadadustat for treating anaemia in people with chronic kidney disease [ID3821] have been revised. It is anticipated that the appraisal will begin in early-August 2023 when we will write to you about how you can get involved. |
|
13 September 2022
|
As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Vadadustat within its marketing authorisation for treating anaemia in people with chronic kidney disease.
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early-August 2023. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
|
28 March 2022 - 27 April 2022
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
|
18 February 2021
|
In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual